In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
The FDA has initiated a review of Moderna’s seasonal influenza vaccine under a revised regulatory framework. The updated approach could influence how next-generation flu vaccines are evaluated, particularly those using mRNA technology. The review marks an important step for Moderna as it looks to expand beyond COVID-19 vaccines and strengthen its position in the broader respiratory market.
Eli Lilly has entered into a $100 million licensing agreement with CSL Limited for anti- IL-6 monoclonal antibody. The deal expands Lilly’s immunology portfolio and reflects continued strategic investment in inflammation-related therapies. For CSL, the agreement provides additional capital and partnership support as the therapy advances.
Finally, Southern Florida is gaining recognition as an emerging biotech hotspot. Once known primarily for real estate and tourism growth, the region is now attracting life sciences investment, research institutions, and startup activity. Industry leaders point to favorable business conditions, academic partnerships, and an influx of scientific talent as key drivers behind the area’s accelerating biotech momentum.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
